98Indexed trials
mesh condition
Bipolar Disorder
Intelligence
Bipolar Disorder intelligence: 98 indexed trials, 21 recruiting studies, 72 sponsors across 40 countries.
21Recruiting
72Sponsors
40Countries
Leading sponsors
Massachusetts General Hospital60 recruiting
University Hospitals Cleveland Medical Center41 recruiting
New York State Psychiatric Institute30 recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.30 recruiting
Eli Lilly and Company30 recruiting
University Hospital, Montpellier22 recruiting
Sunnybrook Health Sciences Centre20 recruiting
University Hospital, Grenoble20 recruiting
Sandoz20 recruiting
National Institute of Mental Health (NIMH)20 recruiting
Sumitomo Pharma America, Inc.20 recruiting
University of Calgary20 recruiting
Geographic activity
United States51trials
France12trials
Canada6trials
Brazil5trials
Russia5trials
China5trials
Spain3trials
Czechia3trials
Italy3trials
Denmark3trials
India3trials
Japan3trials
Leading interventions
Lurasidone3trials
Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)2trials
Lithium2trials
Olanzapine2trials
risperidone2trials
Aripiprazole2trials
Depakote 500 mg DR Tablets (Abbott Laboratories, USA)2trials
Antipsychotic1trials
Antidepressant1trials
Add-on citalopram following optimized methylphenidate1trials
BHV-70001trials
Asenapine1trials
Methodology note
This entity is derived from structured ClinicalTrials.gov conditions and/or MeSH normalization. Counts reflect the current NeuroRisk indexed corpus and are not guaranteed exhaustive global totals.